Table 1 Characteristics of the women from BRCA1/2 families included in the study
From: Mammographic density and breast cancer in women from high risk families
BRCA1/2 mutation carriers | Relatives without mutation | |||||
|---|---|---|---|---|---|---|
Variable | Without BC | BC patients | P valuea | Without BC | BC patients | P valuea |
N = 443 | N = 248 | N = 219 | N = 10 | |||
Affected gene | 0.183 | . | ||||
BRCA1 | 227 (51.2 %) | 114 (46.0 %) | ||||
BRCA2 | 216 (48.8 %) | 134 (54.0 %) | ||||
Age at mammography | 0.909 | 0.907 | ||||
Mean (SD) | 41.6 (11.5) | 41.5 (10.2) | 45.6 (11.8) | 45.2 (11.2) | ||
Body mass index | 0.030 | 0.948 | ||||
<18.5 | 6 (1.4 %) | 7 (2.8 %) | 11 (5.0 %) | 0 (0.0 %) | ||
18.5−24.9 | 259 (58.5 %) | 151 (60.9 %) | 120 (54.8 %) | 7 (70.0 %) | ||
25−29.9 | 110 (24.8 %) | 69 (27.8 %) | 56 (25.6 %) | 2 (20.0 %) | ||
30−34.9 | 49 (11.1 %) | 19 (7.7 %) | 28 (12.8 %) | 1 (10.0 %) | ||
>=35 | 19 (4.3 %) | 2 (0.8 %) | 4 (1.8 %) | 0 (0.0 %) | ||
Unknown | 0 (0.0 %) | 0 (0.0 %) | 11 (5.0 %) | 0 (0.0 %) | ||
Menopausal statusb | 0.239 | 0.576 | ||||
Premenopausal | 310 (70.0 %) | 184 (74.2 %) | 147 (67.1 %) | 7 (70.0 %) | ||
Postmenopausal | 133 (30.0 %) | 64 (25.8 %) | 72 (32.9 %) | 3 (30.0 %) | ||
Type of menopauseb,c | <0.001 | 0.154 | ||||
Natural | 73 (16.5 %) | 53 (21.4 %) | 69 (95.8 %) | 2 (66.7 %) | ||
Surgery | 60 (13.5 %) | 11 (4.4 %) | 3 (4.2 %) | 1 (33.3 %) | ||
Time since menopauseb,c | 0.100 | 1.000 | ||||
<=5 years | 31 (7.0 %) | 19 (7.7 %) | 27 (12.3 %) | 1 (10.0 %) | ||
6−10 years | 34 (7.7 %) | 8 (3.2 %) | 17 (7.8 %) | 1 (10.0 %) | ||
>10 years | 63 (14.2 %) | 35 (14.1 %) | 28 (12.8 %) | 1 (10.0 %) | ||
Unknown | 5 (1.1 %) | 2 (0.8 %) | 0 (0.0 %) | 0 (0.0 %) | ||
Nulliparous | 0.151 | 0.264 | ||||
No | 302 (68.2 %) | 182 (73.4 %) | 167 (76.3 %) | 6 (60.0 %) | ||
Yes | 141 (31.8 %) | 66 (26.6 %) | 52 (23.7 %) | 4 (40.0 %) | ||
Age at first birth, yearsd | 0.110 | 0.464 | ||||
>30 | 75 (16.9 %) | 34 (13.7 %) | 46 (27.5 %) | 0 (0.0 %) | ||
26−30 | 111 (25.1 %) | 64 (25.8 %) | 60 (35.9 %) | 3 (50.0 %) | ||
21−25 | 98 (22.1 %) | 77 (31.0 %) | 53 (31.7 %) | 3 (50.0 %) | ||
<=20 | 18 (4.1 %) | 7 (2.8 %) | 8 (4.8 %) | 0 (0.0 %) | ||
Oral contraceptives | 0.487 | 0.508 | ||||
No | 156 (35.2 %) | 81 (32.7 %) | 58 (26.5 %) | 4 (40.0 %) | ||
Yes | 239 (54.0 %) | 140 (56.5 %) | 130 (59.4 %) | 6 (60.0 %) | ||
Unknown | 48 (10.8 %) | 27 (10.9 %) | 31 (14.2 %) | 0 (0.0 %) | ||
Use of hormone replacement therapyb | 0.613 | 0.246 | ||||
No | 431 (97.3 %) | 238 (96.0 %) | 205 (93.6 %) | 9 (90.0 %) | ||
Current use | 3 (0.7 %) | 3 (1.2 %) | 5 (2.3 %) | 1 (10.0 %) | ||
Past use | 9 (2.0 %) | 7 (2.8 %) | 9 (4.1 %) | 0 (0.0 %) | ||
Use of hormonal preventive treatmentb | 0.349 | |||||
No | 438 (98.9 %) | 243 (98.0 %) | 219 (99.5 %) | 10 (100 %) | ||
Current use | 5 (1.1 %) | 5 (2.0 %) | 1 (0.5 %) | 0 (0.0 %) | ||
Type of mammogram | <0.001 | 0.020 | ||||
Analog | 132 (29.8 %) | 208 (83.9 %) | 62 (28.3 %) | 6 (60.0 %) | ||
Digital | 311 (70.2 %) | 40 (16.1 %) | 157 (71.7 %) | 4 (40.0 %) | ||
Number of projections | <0.001 | 0.069 | ||||
One | 9 (2.0 %) | 6 (2.4 %) | ||||
Two | 34 (7.7 %) | 74 (29.8 %) | 11 (4.7 %) | 3 (25.0 %) | ||
Three | 2 (0.5 %) | 3 (1.2 %) | 1 (0.4 %) | 0 (0.0 %) | ||
Four | 398 (89.8 %) | 165 (66.5 %) | 223 (94.9 %) | 9 (75.0 %) | ||
Mammographic density | 0.001 | 0.316 | ||||
0 % | 6 (1.4 %) | 0 (0.0 %) | 3 (1.4 %) | 1 (10.0 %) | ||
<=10 % | 99 (22.3 %) | 35 (14.1 %) | 44 (20.1 %) | 1 (10.0 %) | ||
11−25 % | 89 (20.1 %) | 47 (19.0 %) | 44 (20.1 %) | 2 (20.0 %) | ||
26−50 % | 151 (34.1 %) | 85 (34.3 %) | 72 (32.9 %) | 3 (30.0 %) | ||
51−75 % | 72 (16.3 %) | 47 (19.0 %) | 37 (16.9 %) | 3 (30.0 %) | ||
>75 % | 26 (5.9 %) | 34 (13.7 %) | 19 (8.7 %) | 0 (0.0 %) | ||
Time of follow upe | <0.001 | 0.924 | ||||
<=1 year | 207 (46.7 %) | 162 (65.3 %) | 103 (47.0 %) | 4 (40.0 %) | ||
1−2 years | 82 (18.5 %) | 30 (12.1 %) | 39 (17.8 %) | 2 (20.0 %) | ||
2−5 years | 94 (21.2 %) | 30 (12.1 %) | 48 (21.9 %) | 3 (30.0 %) | ||
5−10 years | 46 (10.4 %) | 24 (9.7 %) | 22 (10.0 %) | 1 (10.0 %) | ||
>10 years | 14 (3.2 %) | 2 (0.8 %) | 7 (3.2 %) | 0 (0.0 %) | ||
Prophylatic mastectomy | 0.003 | |||||
No | 428 (96.6 %) | 248 (100.0 %) | ||||
Yes | 15 (3.4 %) | 0 (0.0 %) | ||||
Breast cancer features | ||||||
Histology | . | |||||
Ductal in situ | 15 (6.0 %) | 3 (30.0 %) | ||||
Ductal | 187 (75.4 %) | 6 (60.0 %) | ||||
Lobular | 12 (4.8 %) | 1 (10.0 %) | ||||
Medular | 14 (5.6 %) | 0 (0.0 %) | ||||
Others | 18 (7.3 %) | 0 (0.0 %) | ||||
Unknown | 2 (0.8 %) | 0 (0.0 %) | ||||
Type of breast cancer | ||||||
ER/PR+&HER2− | 99 (39.9 %) | 6 (60.0 %) | ||||
HER2+ | 23 (9.3 %) | 1 (10.0 %) | ||||
Triple-negative | 74 (29.8 %) | 1 (10.0 %) | ||||
Unknown | 52 (21.0 %) | 2 (20.0 %) | ||||